[go: up one dir, main page]

PE20080695A1 - Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel - Google Patents

Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel

Info

Publication number
PE20080695A1
PE20080695A1 PE2007000511A PE2007000511A PE20080695A1 PE 20080695 A1 PE20080695 A1 PE 20080695A1 PE 2007000511 A PE2007000511 A PE 2007000511A PE 2007000511 A PE2007000511 A PE 2007000511A PE 20080695 A1 PE20080695 A1 PE 20080695A1
Authority
PE
Peru
Prior art keywords
phenyl
dihydropirazolopyrimidinone
derivatives
inhibitors
alyl
Prior art date
Application number
PE2007000511A
Other languages
English (en)
Inventor
Makoto Bamba
Hidetomo Furuyama
Hiroshi Hirai
Kenji Niiyama
Toshihide Nishibata
Sachie Otsuki
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38655640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080695(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of PE20080695A1 publication Critical patent/PE20080695A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DIHIDROPIRAZOLOPIRIMIDINONA DE FORMULA (I), EN DONDE A ES DE FORMULA (aa1); R1C ES H, ALQUENILO INFERIOR O Q3-A3(R1d)R1e; DONDE A3 ES N; METINO O 1-VINIL-2-ILDENO; Q3 ES UN ENLACE O ALQUILENO INFERIOR; R1d Y R1e SON INDEPENDIENTEMENTE H, HALOGENO, CN, HIDROXILO, ENTRE OTROS; R1 ES ALQUENILO O ALQUINILO INFERIOR; R2 ES FENILO, PIRIDILO O TIENILO EL CUAL PUEDE TENER UN GRUPO A4(R1g)R1h; R5 y R6 SON H, ALQUILO INFERIOR O HIDROXIALQUILO INFERIOR. SON SELECCIONADOS: 3-(2-ALIL-6-{[4-(4-METILPIPERAZIN -1-IL)FENIL]AMINO}-3-OXO-1,2-DIHIDRO-3H-PIRAZOLO[3,4-d]PIRIMIDIN-1-IL)-N,N-DIMETILBENZAMIDA, 2-ALIL-1-[3-(1-HIDROXI-1-METILETIL)FENIL]-6-{[4-(4-METILPIPERAZIN-1-IL)FENIL]AMINO}-1,2-DIHIDRO-3H-PIRAZOLO[3,4-d]PIRIMIDIN-3-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DE QUINASA WEEL Y SON UTILES EN EL TRATAMIENTO DE DIVERSOS CANCERES
PE2007000511A 2006-04-27 2007-04-24 Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel PE20080695A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006124208 2006-04-27

Publications (1)

Publication Number Publication Date
PE20080695A1 true PE20080695A1 (es) 2008-06-28

Family

ID=38655640

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000511A PE20080695A1 (es) 2006-04-27 2007-04-24 Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel

Country Status (39)

Country Link
US (4) US7935708B2 (es)
EP (2) EP2016080B1 (es)
JP (2) JP4513919B2 (es)
KR (1) KR101409161B1 (es)
CN (1) CN101432284B (es)
AR (1) AR060635A1 (es)
AT (1) ATE475662T1 (es)
AU (1) AU2007244185B2 (es)
BR (1) BRPI0710081A2 (es)
CA (1) CA2650119C (es)
CR (1) CR10359A (es)
CY (2) CY1111069T1 (es)
DE (1) DE602007008085D1 (es)
DK (2) DK2016080T3 (es)
DO (1) DOP2007000084A (es)
EC (1) ECSP088812A (es)
ES (2) ES2609087T3 (es)
GT (1) GT200800211A (es)
HK (1) HK1132498A1 (es)
HN (1) HN2008001532A (es)
HR (2) HRP20100563T1 (es)
HU (1) HUE032987T2 (es)
IL (1) IL194367A (es)
LT (1) LT2017278T (es)
MA (1) MA30428B1 (es)
MX (1) MX2008013063A (es)
MY (1) MY145408A (es)
NO (1) NO341617B1 (es)
NZ (1) NZ571196A (es)
PE (1) PE20080695A1 (es)
PL (2) PL2017278T3 (es)
PT (2) PT2017278T (es)
RU (1) RU2437885C2 (es)
SI (2) SI2017278T1 (es)
SV (1) SV2009003060A (es)
TW (1) TWI409262B (es)
UA (1) UA96152C2 (es)
WO (2) WO2007126128A1 (es)
ZA (1) ZA200807748B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080695A1 (es) * 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
JP5411847B2 (ja) * 2007-04-25 2014-02-12 Ｍｓｄ株式会社 Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
WO2008141385A1 (en) * 2007-05-21 2008-11-27 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
WO2009054332A1 (ja) * 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
EP2303885B1 (en) * 2008-06-12 2013-07-03 Merck Sharp & Dohme Corp. Process for producing bicycloaniline derivatives
JP2012511501A (ja) * 2008-12-12 2012-05-24 Ｍｓｄ株式会社 ジヒドロピリミドピリミジン誘導体
WO2010076887A1 (en) * 2009-01-05 2010-07-08 Banyu Pharmaceutical Co.,Ltd. Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
WO2010098367A1 (en) * 2009-02-25 2010-09-02 Banyu Pharmaceutical Co.,Ltd. Pyrimidopyrimidoindazole derivative
US20120157342A1 (en) * 2009-09-02 2012-06-21 Shinji Mizuarai Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
SI2477628T1 (sl) 2009-09-15 2014-11-28 Merck Sharp & Dohme Corp. Priprava oblik kristalinskega hemihidrata dihidropirazolopirimidinona
US9370567B2 (en) 2010-11-16 2016-06-21 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and WEE 1 kinase inhibitors
CN106278943B (zh) * 2011-04-27 2019-07-30 日本瑞翁株式会社 光学薄膜、聚合性化合物、聚合性组合物、高分子、光学各向异性体以及肼化合物
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
EP2755482B1 (en) 2011-09-15 2016-06-01 Merck Sharp & Dohme Corp. Combination of mk-1775 and mk-8776 for treating cancer
WO2013059485A1 (en) * 2011-10-20 2013-04-25 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
JP2015511245A (ja) * 2012-02-23 2015-04-16 アッヴィ・インコーポレイテッド ピリドピリミジノン系キナーゼ阻害薬
WO2014062454A1 (en) * 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
CA2892361A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels
MX2015014249A (es) 2013-04-09 2016-06-02 Lixte Biotechnology Inc Formulaciones de oxabicicloheptanos y oxabicicloheptenos.
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
JP6023902B1 (ja) * 2014-12-17 2016-11-09 Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 高齢又は末期の癌患者を治療又は寛解するための医薬組成物
TW201710257A (zh) 2015-04-17 2017-03-16 艾伯維有限公司 Ｔｎｆ信號傳遞之三環調節劑
UY36629A (es) 2015-04-17 2016-11-30 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
UY36628A (es) 2015-04-17 2016-11-30 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
EP3345907B1 (en) * 2015-09-01 2020-04-22 Taiho Pharmaceutical Co., Ltd. Pyrazolo[3,4-d]pyrimidine compounds or salts thereof
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
JP6692423B2 (ja) * 2015-11-01 2020-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法
CN106271589B (zh) * 2016-06-23 2018-12-28 中山市美捷时包装制品有限公司 一种用于预装阀杆、弹簧、垫片的组装设备
GB201612092D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
CA3037141A1 (en) 2016-09-15 2018-03-22 Boehringer Ingelheim International Gmbh Heteroaryl carboxamide compounds as inhibitors of ripk2
CN106719769A (zh) * 2016-11-28 2017-05-31 山东农业大学 一种含香菇多糖、苯醚甲环唑和噻虫啉的病虫兼治农药组合物
KR20190098995A (ko) 2016-12-08 2019-08-23 릭스트 바이오테크놀로지, 인코포레이티드 면역 반응의 조절을 위한 옥사바이사이클로헵탄
EP3572413B1 (en) * 2017-01-23 2021-11-03 Shijiazhuang Sagacity New Drug Development Co., Ltd. 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-one derivative as wee1 inhibitor
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
WO2018171633A1 (zh) * 2017-03-23 2018-09-27 上海迪诺医药科技有限公司 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用
KR20190130621A (ko) 2017-03-31 2019-11-22 시애틀 지네틱스, 인크. Chk1 저해제와 wee1 저해제의 조합물
MX2020001235A (es) * 2017-08-01 2020-07-20 Recurium Ip Holdings Llc Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
EP3694509A4 (en) 2017-10-09 2021-07-14 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
PL3712150T3 (pl) * 2017-11-01 2024-09-02 Wuxi Biocity Biopharmaceutics Co., Ltd. Związek makrocykliczny służący jako inhibitor wee1 i jego zastosowania
WO2019096322A1 (zh) * 2017-11-20 2019-05-23 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
WO2019134539A1 (zh) * 2018-01-05 2019-07-11 四川科伦博泰生物医药股份有限公司 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
US11479555B2 (en) 2018-02-23 2022-10-25 Newave Pharmaceutical Inc. Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
WO2019169065A2 (en) 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
KR20200130834A (ko) * 2018-03-09 2020-11-20 리커리엄 아이피 홀딩스, 엘엘씨 치환된 1,2-다이하이드로-3H-피라졸로[3,4-d]피리미딘-3-온
CN108653282B (zh) * 2018-06-28 2020-08-14 中国科学院昆明植物研究所 苯并噻唑类及苯并吡咯类化合物在制备抗肿瘤药物中的应用
EP3875460A4 (en) * 2018-10-26 2022-07-20 Wuxi Biocity Biopharmaceutics Co., Ltd. Pyrimidopyrazolone derivative as wee1 inhibitor and use thereof
CN111662283B (zh) * 2019-03-07 2021-11-16 湖南化工研究院有限公司 咪唑并吡啶类化合物及其中间体、制备方法与应用
JP2022528047A (ja) * 2019-03-22 2022-06-08 ショウヤオ ホールディングス（ベイジン） カンパニー， リミテッド Ｗｅｅ１阻害剤、その製造および用途
WO2020210380A1 (en) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
EP3952877A4 (en) 2019-04-09 2022-12-14 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
AU2020266956A1 (en) 2019-04-30 2021-10-28 Wuxi Biocity Biopharmaceutics Co., Ltd. Crystal form of Wee1 inhibitor compound and use thereof
MX2021015572A (es) * 2019-06-28 2022-04-06 Shanghai Pharmaceuticals Holding Co Ltd Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones.
CN112142748B (zh) 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN114599399A (zh) 2019-10-25 2022-06-07 阿斯利康(瑞典)有限公司 治疗癌症的方法
MX2022007628A (es) * 2019-12-20 2022-08-25 Recurium Ip Holdings Llc Combinaciones.
CN113387962A (zh) * 2020-03-12 2021-09-14 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
JP2023531431A (ja) 2020-06-17 2023-07-24 ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド Ｗｅｅ－１阻害剤としてのピラゾロ［３，４－ｄ］ピリミジン－３－オン誘導体
KR102549484B1 (ko) * 2020-12-08 2023-06-29 한국화학연구원 피라졸로피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 관련 질환의 예방 또는 치료용 약학적 조성물
WO2022171088A1 (zh) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物
CN116848117A (zh) * 2021-02-09 2023-10-03 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物
CN116848118A (zh) * 2021-02-09 2023-10-03 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物
CN115197221B (zh) * 2021-04-02 2024-05-24 轩竹(北京)医药科技有限公司 二氢吡唑并嘧啶酮类大环衍生物及其用途
EP4329815A1 (en) 2021-04-29 2024-03-06 Novartis AG Deubiquitinase-targeting chimeras and related methods
CA3214894A1 (en) 2021-04-30 2022-11-03 Yuli Xie Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof
CA3211181A1 (en) 2021-05-28 2022-12-01 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Wee1 inhibitor and use thereof
WO2023041066A1 (zh) * 2021-09-18 2023-03-23 优领医药科技(香港)有限公司 含嘧啶并二氢吡唑啉酮类衍生物、其药学上可接受的盐及其制备方法和应用
CN113880844B (zh) * 2021-09-29 2023-02-14 武汉九州钰民医药科技有限公司 Wee1蛋白激酶抑制剂adavosertib的化学合成方法
CN113735863A (zh) * 2021-09-29 2021-12-03 武汉九州钰民医药科技有限公司 Wee1抑制剂adavosertib的制备工艺
TW202322812A (zh) * 2021-11-01 2023-06-16 大陸商正大天晴藥業集團股份有限公司 吡唑［３，４－ｄ］嘧啶－３－酮類化合物、包含其的藥物組合物及其醫藥用途
CN116462687B (zh) * 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN116836184A (zh) * 2022-03-25 2023-10-03 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN115073460B (zh) * 2022-07-13 2023-07-25 苏州施安鼎泰生物医药技术有限公司 一种嘧啶并[5,4-c][2,6]萘啶衍生物及其制备方法以及药物组合物和应用
CN119497714A (zh) * 2022-07-15 2025-02-21 映恩生物制药（苏州）有限公司 一种嘧啶并五元杂环化合物、其制备方法和用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA07174A (fr) 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2628707B2 (ja) * 1987-08-26 1997-07-09 三井製薬工業株式会社 ピリミジン類及びその薬学的に許容される塩類
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
SK283693B6 (sk) 1990-09-28 2003-12-02 Smithkline Beecham Corporation Spôsob prípravy kamptotecínu alebo jeho farmaceuticky prijateľnej soli
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
EP1501831A1 (en) 2002-04-26 2005-02-02 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
CA2515132C (en) * 2003-02-07 2012-01-03 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrroles useful as inhibitors of protein kinases
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20050250836A1 (en) 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
CA2569530C (en) 2004-07-01 2013-07-30 Daiichi Asubio Pharma Co.,Ltd. Thienopyrazole derivative having pde 7 inhibitory activity
AU2006205851A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel

Also Published As

Publication number Publication date
AU2007244185B2 (en) 2012-10-04
WO2007126122A1 (en) 2007-11-08
DOP2007000084A (es) 2007-12-31
CY1111069T1 (el) 2012-05-23
KR101409161B1 (ko) 2014-06-19
TW200811176A (en) 2008-03-01
MA30428B1 (fr) 2009-05-04
RU2008146759A (ru) 2010-06-10
US20100063024A1 (en) 2010-03-11
PT2016080E (pt) 2010-10-14
DK2017278T3 (en) 2017-02-13
CN101432284A (zh) 2009-05-13
DE602007008085D1 (en) 2010-09-09
HUE032987T2 (en) 2017-11-28
EP2016080A4 (en) 2009-05-13
US20070254892A1 (en) 2007-11-01
CA2650119C (en) 2017-03-14
ATE475662T1 (de) 2010-08-15
US20140303178A1 (en) 2014-10-09
CN101432284B (zh) 2012-08-15
SI2017278T1 (sl) 2017-05-31
NO20084968L (no) 2008-11-26
UA96152C2 (en) 2011-10-10
EP2017278A1 (en) 2009-01-21
DK2016080T3 (da) 2010-11-22
CA2650119A1 (en) 2007-11-08
TWI409262B (zh) 2013-09-21
MX2008013063A (es) 2008-12-16
RU2437885C2 (ru) 2011-12-27
IL194367A (en) 2014-12-31
EP2016080A1 (en) 2009-01-21
WO2007126128A1 (ja) 2007-11-08
EP2017278B1 (en) 2016-11-02
SI2016080T1 (sl) 2011-03-31
MY145408A (en) 2012-02-15
AU2007244185A1 (en) 2007-11-08
US20110189130A1 (en) 2011-08-04
GT200800211A (es) 2009-04-07
HRP20161763T1 (hr) 2017-02-24
JP5167291B2 (ja) 2013-03-21
KR20090017491A (ko) 2009-02-18
JP4513919B2 (ja) 2010-07-28
SV2009003060A (es) 2009-04-28
US7834019B2 (en) 2010-11-16
ES2348751T3 (es) 2010-12-13
PT2017278T (pt) 2017-01-03
HRP20100563T1 (hr) 2010-11-30
EP2017278A4 (en) 2009-04-22
CY1118526T1 (el) 2017-07-12
AR060635A1 (es) 2008-07-02
BRPI0710081A2 (pt) 2011-08-02
CR10359A (es) 2009-02-19
LT2017278T (lt) 2017-01-25
ECSP088812A (es) 2008-11-27
JPWO2007126128A1 (ja) 2009-09-17
US8791125B2 (en) 2014-07-29
NO341617B1 (no) 2017-12-11
ES2609087T3 (es) 2017-04-18
ZA200807748B (en) 2009-10-28
EP2016080B1 (en) 2010-07-28
HK1132498A1 (en) 2010-02-26
HN2008001532A (es) 2009-06-10
IL194367A0 (en) 2009-08-03
PL2016080T3 (pl) 2011-03-31
US7935708B2 (en) 2011-05-03
NZ571196A (en) 2011-03-31
PL2017278T3 (pl) 2017-10-31
JP2010132689A (ja) 2010-06-17

Similar Documents

Publication Publication Date Title
PE20080695A1 (es) Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
PE20080944A1 (es) Derivados de pirimidina como inhibidores del receptor de cinasa activina(alk-5)
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20220597A1 (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20090741A1 (es) Derivados de 1,1,1-trifluor-2-hidroxi-3-fenilpropano
EA200800441A1 (ru) Замещенные бензимидазолы в качестве ингибиторов киназ
EA200800018A1 (ru) Аминопиримидины в качестве модуляторов киназы
TR201906123T4 (tr) P13 kinazı ve mtor inhibitörleri olarak triazin bileşikleri.
PE20090902A1 (es) Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos
PE20071138A1 (es) Derivados de pirimidina como inhibidores de quinasas
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
PE20091116A1 (es) Derivados de piridina y pirazina como inhibidores de tirosina quinasas
EA200701853A1 (ru) Производные циклопентапиридина и тетрагидрохинолина
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
PE20110153A1 (es) Derivados de piridazina como inhibidores de smo
PE20091268A1 (es) Derivados heterociclicos como inhibidores de pi3 quinasa
PE20080275A1 (es) Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa
PE20091527A1 (es) Derivados de piridazinona
ATE484501T1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
PE20090110A1 (es) Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90
PE20070795A1 (es) Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa

Legal Events

Date Code Title Description
FG Grant, registration